Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
使用《赢家江恩软件》官方看图分析该股>>
满脑袋高粱花子
亚虹医药Asieris（688176.SH）| DJSeedin创新合作峰会上市公司路演汇报
亚虹医药Asieris将参加11月3日下午
上市公司路演专场，汇报时间20分钟。
亚虹医药成立于2010年3月，是一家专注于泌尿生殖系统肿瘤及其它重大疾病领域的全球化创新药公司。秉承“改善人类健康，让生命更有尊严”的企业使命，亚虹立志成为在专注治疗领域集研发、生产和商业化为一体的国际化制药企业，为中国和全球患者提供诊疗一体化解决方案。
公司坚持以创新技术和产品为核心驱动力，通过打造自有的研发平台和核心技术，深入探索药物作用机理，高效率筛选评价候选药物。通过内部完善的研发体系和全球药物开发经验专长，亚虹致力于在专注治疗领域推出First-in-Class药物和其它存在巨大未被满足治疗需求的创新药物。同时，亚虹通过自主研发和战略合作，围绕泌尿生殖系统疾病进行产品管线的深度布局，高度关注该领域的技术前沿和治疗发展趋势，洞察并挖掘未被满足的临床需求，前瞻性地进行产品规划和生命周期管理，打造涵盖疾病诊断到治疗的优势产品组合，从而造福更多的中国和全球患者。
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus. Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
DJSeedin创新合作峰会是由新药研发专业商业息机构研发客（PharmaDJ）与生物医药知识服务平台柏思荟（bioSeedin）于2021年共同发起的中国生物医药投资和交易年度盛会。
2022年11月3-4日，第二届DJSeedin创新合作峰会将正式拉开帷幕。现场将超过60家公司现场路演，分为上市公司路演专场，临床阶段公司专场、早期创新技术公司专场和Innovation Incubate专场，为大家带来企业最新发展动向、技术平台研发进展和临床数据汇报。
现场将聚集500+ 家biotech，pharma，therapeutic R&D，CRO，CDMO，Investment 公司。观众1000+ 人，来自各大药企C-suite、BD和投资机构以及证券公司合伙人、投资总监。
除了面对面的路演、交流活动以外，我们还提供了1-ON-1商务洽谈系统，报名观众可通过1ON1商务洽谈系统与现场路演公司发言人、参会药企代表和各大投资机构负责人预约会面和深入交流。
我们希望这个会议品牌不仅是中国创新药公司的舞台，也成为整个行业的风向标，为中国创新药公司搭建交易、融资、合作平台，并向世界展示中国不可估量的重要影响。
分享：
相关帖子